Narayana Hrudayalaya Ltd
Narayana Hrudayalaya Ltd. engages in the provision of medical and health care services. The company is headquartered in Bangalore, Karnataka and currently employs 11,726 full-time employees. The company went IPO on 2016-01-06. The firm operates a network of hospitals, diagnostic centers, clinical centers or test laboratories. The firm operates through Medical and Healthcare Services business segment. The firm offers medical, surgery, and diagnostics and support services. The company provides services in the areas of cardiology; orthopedics; cosmetic surgery; anesthesia; imaging and radiology; nutrition and dietetics; physiotherapy; renal transplant; thoracic surgery; pediatrics surgery; medical oncology; surgical gastroenterology; dermatology; hematology; rheumatology; neurology; psychiatry and psychology, and others. The firm operates a network of approximately 20 hospitals (multispecialty and super specialty healthcare facilities), four heart centers and 19 primary care facilities (including clinics and information centers), across India and a hospital at Cayman Islands with approximately 6,181 operational beds.
Price Trend & Technical Volume
Daily QuotesPrice Chart (Historical Trend)
Interactive index-style Recharts with entry animations
4V Matrix
Multi-dimensional proprietary scoreValuation Comparison
Intrinsic & Fair Value Multiples* DCF valuation criteria: 2-Stage model: 10% growth rate years 1-5, 10.5% discount rate, 3% terminal growth rate
Community Sentiment
Be the first to voteWhat is your outlook on Narayana Hrudayalaya Ltd? Anonymous community voting — click an option to cast or update your vote.
AI Diagnostics Score
Weighted model combining fundamental, technical & growth factors.
- Debt/Equity is within safe range (1.07).
- Piotroski financial solvency score: 5/9.
- Momentum metrics indicate consolidation near key averages.
Historical Returns
Growth Analysis
| Metric | 1-Yr YoY | 3-Yr CAGR | 5-Yr CAGR |
|---|---|---|---|
| Sales | +44.0% | +20.4% | +25.1% |
| Profit | +1.9% | +9.9% | — |
Institutional Valuation Models & Fundamental Quality Methodology
DesiStocks synthesizes classical institutional valuation models and financial distress frameworks to provide a balanced, multi-dimensional view of Indian equity fundamentals. Review each methodology below to understand its core drivers, appropriate use cases, and inherent assumptions.
Projects operating cash flows minus capital expenditures over a 5-year forecast window, discounted back to present value using the Weighted Average Cost of Capital (WACC). Terminal value assumes a sustainable 4% perpetual growth rate matching India's long-term GDP expansion.
Rooted in classic value investing doctrine: √(22.5 × EPS × Book Value). Graham's formula sets a defensive price ceiling to ensure an investor never pays more than 15x earnings and 1.5x tangible book value simultaneously.
Anchored in Growth at a Reasonable Price (GARP). Equates a fair P/E multiple directly to the sustainable earnings growth rate percentage: Fair Price = EPS × Growth Rate. A PEG below 1.0 signifies potential undervaluation relative to growth.
Nine binary financial tests across profitability (positive ROA, cash flow > net income), balance sheet leverage (declining debt, rising liquidity, zero share dilution), and operational efficiency (improving gross margin and asset turnover). High scores (8–9) confirm robust quality.
Five weighted financial ratios assessing working capital, cumulative profitability, operating leverage, market capitalization, and asset turnover. Proven predictor of balance sheet stress and corporate bankruptcy probability over a 24-month horizon.
Proprietary four-pillar diagnostic framework examining Valuation (multiples vs 5Y history), Value Creation (ROCE spread over WACC cost of capital), Volatility (drawdown containment & beta), and Velocity (operating profit momentum).
All intrinsic valuations and scores are mathematical models generated using publicly available financial statements and historical market disclosures. These calculations do not represent guaranteed future price targets, investment advice, or research analyst buy/sell ratings under SEBI (Research Analysts) Regulations. Always perform independent diligence and consult a licensed financial advisor.